N/A N=59 Effects of Eszopiclone on Sleep and Memory in Schizophrenia
Schizophrenia
Primary: Sleep Spindle Density — 2.02; 2.13; 2.25; 2.44 Sleep spindle density (number/minutes)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=128 Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)
Blister of Foot
Primary: Count of Participants With Any Foot Blister in Taped or Untaped Area of the Foot — 106; 30; 81 Participants
Phase 2 N=31 A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rate (ORR) — 3 percentage of participants
Phase 2 N=132 Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 5.3; 6.9 months
Phase 4 N=92 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
Phase 3 N=143 Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence
Smoking Cessation · Alcohol-Related Disorders
Primary: Smoking Abstinence — 19; 21; 12; 9 participants
Phase 2 N=66 Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
Cannabis Dependence · Cannabis Withdrawal
Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…
N/A N=135 Needle Guidance in Ultrasound Guided Nerve Blocks
Elective Knee Surgery
Primary: Time Spent in Performing Ultrasound Guided Femoral Nerve Blocks With InfinitiPlusTM Needle Guidance System — 118; 177 seconds — p=< 0.001
N/A N=186 Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia
Pre-eclampsia
Primary: Detection of Fluid in the Lungs — 2; 3 Participants — p=.162
N/A N=197 Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptom
Primary: Efficacy: Change From Baseline in the International Prostate Symptom Score (IPSS) at 3 Month Follow-Up — -11.2; -4.3 Cange in IPSS score
N/A N=68 China Antiretroviral Treatment Adherence for Life
HIV Infections
Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time
Phase 4 N=114 The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty
Total Knee Replacement
Primary: Number of Days Until a Dry Wound — 3.6 days
N/A N=30 Correlation of Mesalamine Pharmacokinetics With Local Availability
Local Drug Concentration in Gastrointestinal Tract
Primary: The AUC of Mesalamine in Plasma — 40.8; 57.6; 36.8; 7.9 nM*h
N/A N=40 User Evaluation of the MiniMed 640G Insulin Pump
Type 1 Diabetes · Type 2 Diabetes
Primary: User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link Transmitter — 6.02 units on a scale
Phase 2 N=57 A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
Malignant Melanoma
Primary: Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months — 38.6 percentage of participants